Amarin up as European CV groups include Vascepa in practice guidelines

The European Society of Cardiology and European Atherosclerosis Society have updated their clinical practice guidelines for managing dyslipidemias to include finding from the REDUCE-IT study, including the recommendation that Amarin’s (NASDAQ:AMRN) Vascepa (icosapent ethyl), 2g twice daily, be considered for high-risk patients with cardiovascular (CV) disease with triglyceride levels between 135 mg/dL and 499 mg/dL despite treatment with statins.

https://seekingalpha.com/news/3496235-amarin-1-percent-premarket-european-cv-groups-include-vascepa-practice-guidelines